<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363179">
  <stage>Registered</stage>
  <submitdate>22/10/2012</submitdate>
  <approvaldate>23/10/2012</approvaldate>
  <actrnumber>ACTRN12612001131842</actrnumber>
  <trial_identification>
    <studytitle>A trial to evaluate the effects of a D-xylose preload, with or without sitagliptin, on incretin hormone secretion, gastric emptying, and postprandial glycaemia in patients with type 2 diabetes mellitus.</studytitle>
    <scientifictitle>A randomised placebo controlled crossover trial to evaluate the effects of a D-xylose preload, with or without sitagliptin, on incretin hormone secretion, gastric emptying, and postprandial glycaemia in patients with type 2 diabetes mellitus.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Each subject will undergo four study visits, in which they will receive a sweet "preload" drink, containing either 50g D-xylose or 80mg sucralose (negative control), after receiving either 100mg sitagliptin or placebo. The four studies will occur in double-blind, randomised fashion, separated by 3 days.  Sitagliptin or placebo tablets will be taken at 2200 the evening before each study, and the sweet preload will be consumed the following morning, between T=-40 to -38 min, before a mashed potato meal (65g powdered potato and 20g glucose reconstituted with 200mL water and one egg yolk containing 13C octanoic acid) consumed between T=0 to 5 min.</interventions>
    <comparator>80mg sucralose preload (equivalent sweetness to D-xylose preload); matching placebo tablet (identical to sitagliptin tablet).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood glucose concentration</outcome>
      <timepoint>T = -40, -20, 0, 15, 30, 60, 90, 120, 180 and 240 min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma active GLP-1 concentration</outcome>
      <timepoint>T = -40, -20, 0, 15, 30, 60, 90, 120, 180 and 240 min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gastric half-emptying time measured by breath test after labelling the potato meal with 13C octanoic acid</outcome>
      <timepoint>Breath samples at immediately before the potato meal and then every 5 min for the first hour after, then every 15 min for a further 3 hours.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with type 2 diabetes mellitus</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Medications affecting gut function; Alcohol intake &gt;20g daily or cigarette smoking; Significant gastrointestinal disease or surgery; Impaired liver or renal function; Blood donation within 3 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>computer-generated random number table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/11/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress>North Terrace Adelaide South Australia 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council GPO Box 1421 Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will evaluate the effects of a D-xylose preload, with or without sitagliptin, on incretin hormone secretion, gastric emptying, and postprandial glycaemia in patients with type 2 diabetes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 3, Hanson Institute Royal Adelaide Hospital, North Terrace, Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>18/11/2011</ethicapprovaldate>
      <hrec>110924</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>